ado-trastuzumab-emtansine
UK Researchers ID Potential Biomarker of Response to Herceptin in Overweight Breast Cancer Patients
Premium
The study, conducted at the University of Southampton, homed in on crown-like structures of immune cells on the border of body fat and tumor tissue as a biomarker for anti-HER2 drug response.
Roche Q4 Pharmaceutical Revenues Up 14 Percent as Perjeta Maintains Top Spot Among Oncology Drugs
The pharmaceutical division contributed CHF 11.66 billion to Q4 2021 revenues compared to CHF 10.22 billion during Q4 2020.
ESMO Data in HER2-Positive Lung, Breast Cancer Bolster Daiichi Sankyo, AstraZeneca's Enhertu
Premium
Studies showed that the antibody-drug conjugate benefited HER2-mutated NSCLC patients and outperformed Genentech's T-DM1 in HER2-positive, previously treated breast cancer.
Roche Q2 Pharmaceutical Revenues Increase 4 Percent
Increasing revenues from newer oncology drugs like atezolizumab and strong diagnostics division revenues helped diminish the impact of the pandemic.
Daiichi Sankyo, AstraZeneca Begin Head-to-Head Breast Cancer Trial of Enhertu, Kadcyla
The Phase III trial will compare Enhertu against Kadcyla as an adjuvant treatment for early-stage HER2-positive breast cancer patients.